Business Wire

GCCA

10.5.2022 01:03:12 CEST | Business Wire | Press release

Share
Global Cement Industry Announces New Programme of Support for Sustainable Technologies – as ‘Open Challenge’ for Brightest Innovation Start-ups Unveils First Partnerships

The Global Cement and Concrete Association (GCCA) has today revealed the first six start-ups that will be backed by its member companies as part of the first ever Innovandi ‘Open Challenge’ in the race to ‘net zero’ by 2050.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005690/en/

The six start-ups, which were chosen from more than 100 entrants to the Open Challenge, hail from the USA, Canada, UK, Italy and the Netherlands. They have now joined forces with world-leading cement companies to help drive further innovation in the industry and will each form part of formal consortia to further test, develop and deploy their ground-breaking technologies.

One of the key focuses of the industry is to develop the technology and implementation for carbon capture, utilisation and storage (CCUS), with CarbonOrO, MOF Technologies and Saipem among the start-ups that the industry is backing. GCCA members have committed to moving from the dozens of pilot projects and announcement already underway to having 10 industrial scale carbon capture plants by 2030 as part of the landmark Net Zero Roadmap, announced in October 2021. CCUS includes a range of technologies and methods that “capture” CO2 from large sources – such as in industrial power generation. The CO2 is then either used on site or compressed and transported to be used or stored elsewhere.

Carbon Upcycling Technologies and Fortera both use captured CO2 to produce low-carbon cement and cementitious materials. The other confirmed start-up is Coomtech, a British business that has developed a low-cost drying technology using kinetic energy created by managed, turbulent air.

Six newly established consortia will help to accelerate the development of technologies that reduce or eliminate carbon throughout the cement and concrete value chain. Each consortium is made up of a start-up company, with their respective pioneering technology, and includes between three and eight cement companies, with 16 GCCA member companies involved across the six innovation consortia.

Thomas Guillot, GCCA Chief Executive , said: “It’s a proud moment to see the industry coming together to support such innovative start-ups on their journey. Our member companies were greatly impressed by their ambition to be a key part of the climate solution. The programme is another big step forward towards unlocking innovation to help us achieve our net zero goal.

“As the need for resilient and sustainable communities to support a growing global population becomes more pressing, cement and concrete will be essential to providing the infrastructure and buildings that society needs. Achieving net zero concrete relies on a number of different groups playing their part, and as an industry we’re looking outwards as well as inwards, to see how start-ups like these can support our goals.

"To achieve net zero globally by 2050, we also need to involve and support the future generations who contribute innovative ideas and energy to the industry. At GCCA, we’re identifying and convening research and development with great potential and offering our support through guidance and effective collaboration.”

These young start-ups are the future generation to help accelerate the industry’s progress, and as an accelerator of the United Nations (UN) Race to Zero campaign, GCCA continues to support innovative development to achieve net zero concrete globally.

The members of each consortia are working together to develop their technologies ahead of a demonstration day, scheduled for late 2022. GCCA worked with Techstars, the worldwide network that helps entrepreneurs succeed, to identify start-ups for the challenge. To find out more about the Innovandi programme please visit https://gccassociation.org/innovandi/ .

ENDS

About the Innovandi Open Challenge

Launched in 2021 the Open Challenge is a key part of the industry’s commitment to achieve net zero. This first-ever edition provides the platform for start-ups to drive innovation in the cement and concrete sectors. The Open Challenge focuses on developing carbon capture and calcination technologies, as well as improving carbon use in the construction supply chain and the recycling process of concrete. By partnering with the start-ups, member companies will provide them with their global resources and the support they need to grow and refine their product.

Shortlisted start-ups that have not yet formed formal consortia are being mentored by GCCA to help develop their technologies. Further consortia are expected to be announced in the course of the next weeks.

In addition to the formal consortia, the Open Challenge has led to two GCCA members (Cementos Argos and Holcim) supporting Minus Materials as industrial partners in the US Department of Energy ARPA-E grant for $3 million.

The six shortlisted start-ups are:

  • CarbonOrO (The Netherlands)
    • Carbon capture technology using unique bi-phasic amine with a lower cost of capture.
    • Supported by CEMEX, Holcim, SCG, Titan Cement, UltraTech Cement and Votorantim Cimentos.
  • Carbon Upcycling Technologies (Canada)
    • Using a patented, low-energy process, Carbon Upcycling Technologies chemically activates and captures CO2 within solid waste materials to produce a range of supplementary cementitious materials, to create low carbon cement and concrete.
    • Supported by Cementos Argos, CEMEX, CRH, Holcim, Shree Cement and Taiheiyo.
  • Coomtech (UK)
    • Coomtech has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture.
    • revolutionising a 100-year-old process, a single Coomtech-enabled plant can cut CO2 emissions by the equivalent of more than 600,000 mature trees per year and is 75% cheaper to operate.
    • Supported by Buzzi Unicem, CRH, JSW Cement and UltraTech Cement.
  • Fortera (USA)
    • Fortera’s technology captures CO2 emissions from cement plants, combining it with calcium to make reactive calcium carbonate. It is stable in dry powder form and its cementitious properties are activated when wetted.
    • Supported by Cementos Argos, CRH, Holcim, JSW Cement, Taiheiyo Cement and Ultratech Cement.
  • MOF Technologies (UK)
    • Nuada carbon capture technology uses Metal-Organic Frameworks (MOFs) to deliver energy-efficient CO2 removal at a fraction of the cost of conventional amines
    • Supported by Buzzi Unicem, Cementir Holding and HeidelbergCement,
  • SAIPEM (Italy)
    • Saipem has developed a revolutionary carbon capture technology using a non-volatile aqueous carbonate solution catalysed by enzymes that neither require nor produce toxic products. The process can capture post-combustion emissions directly from industrial sources, like chimneys, using low-grade residual heat to drive the process.
    • Supported by Buzzi Unicem, Cementir Holding, Cementos Molins, CEMEX, GCC, Holcim, Titan Cement and Votorantim Cimentos.

Supporting quotes

Start-ups

Jan Hoppenbrouwers, Co-Owner and Head of Sales & Marketing, CarbonOrO
“There is a lot of talk about CCUS, but worldwide, there is only a limited number of active test projects lined up so far. With so little time left, this makes you wonder. GCCA members and their consortia’s joined efforts have all the characteristics to change this. Thank you for that.”

Natalie Giglio, Senior Business Development Associate, Carbon Upcycling Technologies
“At Carbon Upcycling, we've created a novel technology that uses CO2 as a resource rather than a waste for the cement industry. By using abundant, local waste materials and CO2 directly from cement kilns, we enable circularity within local supply chains. Participating in the Innovandi Open Challenge has given us a platform to take our ready-to-deploy technology and accelerate its pathway to global commercialisation."

Chris Every, Chief Commercial Officer & Founder, Coomtech
“As a young business seeking to establish a radical new technology there is usually no short cut to the industries you are targeting or clients you seek to inform and demonstrate capability to. Each prospect must be individually developed and nurtured. The Innovandi Open Challenge combines a stringent review process with access to the combined power of the biggest global players in the cementitious market. The Challenge provides those of us who have succeeded in clearing the evaluation hurdles along the way, a unique and hugely valuable direct access to our prospective markets and technology users. We are delighted and proud to have been selected as a consortium partner in the Innovandi Open Challenge and are excited to begin the execution stage, delivering Coomtech’s contribution to a cleaner and more cost-effective cement industry.”

Ryan Gilliam, CEO, Fortera
“We’re very pleased that our technology has been chosen by the Innovandi Open Challenge for industry collaboration. Fortera has developed a process for manufacturing cost-competitive, low-carbon cement at a time when net-zero solutions are urgently needed. We look forward to our collaboration with GCCA partners in furthering climate-friendly alternatives that deliver the cost and performance of Portland cement while sequestering carbon within the built environment.”

Dr. Conor Hamil, Co-CEO, MOF Technologies
“Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to be working with members of the GCCA to bring our technology to the field. Our Nuada carbon capture technology has been designed to deliver the ultra-efficient CO2 separation needed to overcome these barriers, enabling our partners to reach their net zero targets. We are therefore thrilled to be participating in the Innovandi Open Challenge and playing our part in decarbonising the concrete value chain.”

Saipem
“Saipem is proud to attract GCCA members’ interest in its unique enzymatic carbon capture technology. GCCA’s open innovation program positively contributes to accelerating the adoption of carbon capture technologies. SAIPEM will work with GCCA consortium members to improve from traditional carbon capture technologies’ environmental and energy footprint, helping the cement sector decarbonize its operations competitively while positively impacting many other hard-to-abate industrial sectors. This recognition further confirms Saipem’s leading role in the CCUS sector, where Saipem has the competencies, skills, assets and technologies to serve the entire value chain.”

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye